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EDITORIAL COMMENT
Combination Therapy for
Acute Myocardial Infarction
Will it Survive?*
Neal S. Kleiman, MD, FACC
Houston, Texas
Three years ago, the combination of a fibrinolytic agent
given in a reduced dose, and a glycoprotein (GP) IIb/IIIa
antagonist was trumpeted as a “great equalizer,” with the
potential to bring the success rates for pharmacologic
reperfusion regimens into line with those observed for
mechanical reperfusion regimens. The promise was obvious.
More rapid restoration of coronary flow and more stable
reperfusion could be obtained. Consequently, myocardium
could be preserved and lives could be saved. In fact, shortly
after the presentations of the Thrombolysis In Myocardial
Infarction (TIMI) 14 pilot study (1), many institutions
began using combination therapy, even before data were
available to indicate that patients benefited from this com-
bination. Unfortunately, the clinical data to date have failed
to support the pilot data.
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Shortly after the description of platelet GP IIb/IIIa
(integrin IIb3), antagonists to the receptor were devel-
oped. It is worth noting that the initial therapeutic appli-
cation was to be augmentation of thrombolysis. A basic
model was partially in place. Patients with acute myocardial
infarction, particularly those receiving thrombolytic drugs,
have evidence of increased platelet activation and increased
platelet aggregation. One pathologic study from the Na-
tional Heart, Lung, and Blood Institute has indicated that
patients who manifest thrombolytic failure (death) are three
times as likely to have platelet-rich thrombi as patients who
die but who have not received thrombolytic therapy (2).
Subsequently, a variety of animal models, particularly those
studied by Gold and others (3,4) took this concept one step
forward. A canine model of thrombosis was constructed,
and thrombolysis was achieved using multiple bolus doses of
tissue-type plasminogen activator (t-PA). Administering an
antibody directed at platelet GP IIb/IIIa [7E3F(ab)2, a
precursor of abciximab] allowed patency to be achieved and
sustained using fewer boluses of t-PA and was particularly
effective when thrombi proved to be t-PA resistant (5).
These observations led to two important concepts. First,
platelets exhibited a threshold response to the GP IIb/IIIa
antagonist (approximately 80% receptor blockade was re-
quired to limit thrombosis), and second, when this thresh-
old was achieved, the total dose of fibrinolytic agent,
measured as the number of boluses of t-PA required to
achieve patency, could be reduced.
The first clinical studies of this principle followed the
experimental observations by nearly a decade. Currently, five
small studies (1,6–9), six including the current one, have
been published. All but one indicate increases in that
favorite surrogate end point, TIMI grade 3 flow, in patients
receiving combination therapy compared with those receiv-
ing a standard dose of a fibrinolytic agent. Unfortunately,
the large clinical trials have not supported the enthusiasm
engendered by these findings. One large trial, GUSTO V
(10), revealed no reduction in mortality by a combination of
reduced dose reteplase and abciximab at 30 days, although
there was a substantial reduction in the rate of reinfarction
among patients receiving combination therapy. However, at
the end of one year, the mortality rates were absolutely
identical (odds ratio 1.000). A smaller study, ASSENT III
(11), compared a combination of reduced dose tenecteplase
(TNK) with abciximab. Similarly, no mortality benefit was
present.
Where, then, do these findings leave us? The theoretical
basis for this therapeutic approach has been established; the
experimental evidence supporting it is secure, and the
clinical principle has been confirmed in pilot studies. Un-
fortunately, the acid test has not been passed. Although we
may never know the reason, there are multiple potential
explanations. From a clinical point of view, safety concerns
may at least in part offset efficacy gains. Patients in pilot
studies of new therapeutic regimens are usually selected very
carefully. Consequently, risks are underestimated compared
with in larger trials, which are directed at broader patient
bases. In both GUSTO V and ASSENT-3, the risk of
bleeding was significantly increased, particularly in elderly
patients.
In addition to considering the balance between risk and
benefit, the paradigm of inhibiting platelet aggregation
deserves a careful look for several reasons. First, the effect of
thrombolytic agents on platelet function is not clear. There
is little doubt that platelet activation increases when fibrino-
lytic agents are administered; however, the degree and time
course over which platelet aggregation is affected are con-
troversial. Both increases as well as decreases in aggreg-
ability have been reported, and varying effects of fibrinolytic
agents and their indirect mediator, plasmin, also have been
noted (12). Other effects also may be important. Although
combination therapy clearly decreases platelet aggregation,
it has little if any effect on platelet activation. Platelets
activated during the fibrinolytic and reperfusion processes
may continue to secrete a variety of vasoconstrictor and
inflammatory mediators that may affect the distal vascula-
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ture and/or the myocardium. Furthermore, an important
under-recognized fact is the role that white blood cells may
play in the thrombotic process (13). Glycoprotein IIb/IIIa
antagonists may or may not alter cross talk between acti-
vated platelets and white blood cells. Finally, distal embo-
lization of fragmented thrombus may occur, as well.
The current manuscript by Giugliano et al. (14) in this
issue of the Journal should be viewed in this light. The
investigators of the INTEGRITI trial performed a careful
dose-finding study in which eptifibatide was combined with
reduced-dose tenecteplase. In the dose confirmation phase
of the trial, 249 patients received either monotherapy with
TNK or combination therapy with half-dose TNK and
eptifibatide given as dual 180 g/kg boluses and a 2
g/kg/min infusion. It is worth noting that of all the
combination regimens that have been tested, this dose of
eptifibatide provides the greatest degree of inhibition of
platelet aggregation, at least when standard turbidimetric
measures of platelet aggregation are used (15). Perhaps the
most telling result of the trial lies in the last portion of the
last figure within the paper. Sixty minutes after beginning
treatment, there were important trends toward increased
frequency of TIMI flow grade 3, TIMI myocardial perfu-
sion grade 3, and complete ST resolution among patients
receiving combination therapy compared with those receiv-
ing TNK monotherapy. However, the authors very astutely
asked in how many patients all three indicators of reperfu-
sion were present—in only 23% of patients were all three
indicators of restoration of flow to the myocardium found.
Although better than that observed in patients receiving
TNK monotherapy, this figure is still disappointing.
Looked at another way, reperfusion fails to occur in three-
fourths of patients receiving combination therapy and nearly
90% of those receiving monotherapy. In other words, even
with the most aggressive of pharmacologic regimens, early
complete reperfusion is rare.
Where are we left, then? Based on the studies done, it
seems unlikely that combination therapy alone will offer
much advantage over thrombolytic monotherapy. Perhaps it
was naive to expect that it would. Based on findings from
the first GUSTO study, Simes et al. (16) calculated that a
20% improvement in TIMI grade 3 flow resulted in a 1%
improvement in all-cause mortality, given a baseline mor-
tality of 7.3%. Perhaps it has been naive to expect a second
reduction of equivalent proportions. It is not known
whether the curve relating improvement in TIMI grade 3
flow with mortality is linear. That is, a further 20%
increment in TIMI 3 flow may or may not result in an
additional 1% decrement in mortality. The observed incre-
ment in TIMI grade 3 flow for combination therapy is
closer to 10% to 15%. Furthermore, this model does not
account for potential increases in the hazard of treatment
when more aggressive reperfusion regimens are studied.
Does all this mean that combination therapy is moribund
and that GP IIb/IIIa antagonists will never be useful for
reperfusion in patients with acute myocardial infarction?
Hardly. It may well be that immediate mechanical revascu-
larization emerges as the “savior” of combination therapy.
Early restoration of coronary flow using combination ther-
apy may facilitate primary percutaneous intervention (PCI).
Although nearly every comparison between primary PCI
and fibrinolysis has indicated that the former treatment
(without fibrinolytic or GP IIb/IIIa adjunct) is superior, one
wonders what the findings would be if the same analysis
used in Giugliano’s Figure 4 were performed in patients
undergoing primary PCI. How many patients undergoing
primary PCI would have TIMI grade 3 flow, TIMI perfu-
sion grade 3, and complete ST segment resolution? Obser-
vational data from both the PACT trial (17) as well as the
PAMI studies (18) have indicated that, among patients who
undergo successful primary PCI, left ventricular function
and survival appear to be improved when TIMI grade 3 flow
is present before the intervention begins. Reasons likely
include improved myocardial salvage as well as technically
easier aspects of the intervention. These observations, cou-
pled with the track record of GP IIb/IIIa antagonists during
nonemergent PCI, lend theoretical support to the concept
of “facilitated” angioplasty. Currently, only a single obser-
vational study of facilitated angioplasty has been reported
(19), although several trials evaluating this approach are
currently either underway or in planning stages. Perhaps in
the coupling of these two strategies, the initial enthusiasm
surrounding GP IIb/IIIa antagonists in combination with
fibrinolytic drugs will ultimately be justified.
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